Eye­Point and Rally­bio shake hands on col­lab­o­ra­tion; Sh­iono­gi ex­pects bil­lions for Covid an­tivi­ral pill — re­port

Eye­Point Phar­ma­ceu­ti­cals and Rally­bio will be en­ter­ing in­to a part­ner­ship.

The deal will look at the de­liv­ery of Rally­bio’s C5 in­hibitor us­ing Eye­Point’s tech for in­traoc­u­lar drug de­liv­ery, dubbed Durasert. The re­search will fo­cus on ge­o­graph­ic at­ro­phy, an ad­vanced form of mac­u­lar de­gen­er­a­tion that can even­tu­al­ly lead to vi­sion loss.

Both com­pa­nies al­so in­tend to ex­pand up­on the col­lab­o­ra­tion fol­low­ing the ini­tial re­search work. How­ev­er, no fi­nan­cial de­tails have been giv­en yet. In a re­lease, Rally­bio CEO Stephen Uden said that the use of C5 in­hibitors has al­ready shown “great promise.” While Jay Duk­er, pres­i­dent and COO of Eye­Point, said that the col­lab­o­ra­tion hopes to use the tech­nol­o­gy to pro­vide a more “de­sir­able op­tion” for pa­tients — as the cur­rent ther­a­py is in­ject­ed every one to two months.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER